Featured Research

from universities, journals, and other organizations

Clinical trial tests new treatment for rare cancer

Date:
October 15, 2013
Source:
University of Michigan Health System
Summary:
Adrenal cancer researchers are seeing the results of their laboratory studies translate to a clinical trial to test a potential new therapy in patients.

One of the most challenging cancers to treat is also one of the rarest, which only adds to the challenge of finding potential new therapies.

Related Articles


Now adrenal cancer researchers at the University of Michigan Comprehensive Cancer Center are seeing the results of their laboratory studies translate to a clinical trial to test a potential new therapy in patients.

Researchers Tom Kerppola, Ph.D., and Gary Hammer, M.D., Ph.D., collaborated to test a new compound, ATR-101, in cell lines and mice. Their studies found that ATR-101 selectively killed the adrenal and adrenal cancer cells with very little effect on other cells in the body.

Less than a year after these findings, ATR-101 is now in a phase I clinical trial at the University of Michigan Comprehensive Cancer Center and the University of Texas MD Anderson Cancer Center, testing the safety of the compound in people with advanced adrenocortical carcinoma. The trial, which is the first time this compound is being tested in humans, will enroll 21 participants. The drug is a pill taken orally.

The ATR-101 study is offered by Atterocor Inc., a Michigan-based company that was co-founded by Hammer to develop new adrenal cancer therapies. Hammer serves as a consultant to Atterocor and is chairman of the scientific advisory board. He is not involved in the clinical trial at U-M.

"Many adrenal cancer patients are desperate for new therapeutic options, and ATR-101 is one of the few compounds in the world directed at this ultra-rare disease," says Gary Hammer, M.D., Ph.D., Millie Schembechler Professor of Adrenal Cancer at the U-M Comprehensive Cancer Center.

Hammer's endowed professorship is the result of years of fundraising by legendary U-M football coach Bo Schembechler, whose wife Millie died of adrenal cancer. This funding directed specifically at adrenal cancer has allowed U-M to create a level of expertise -- both research and patient care -- in this extremely rare disease.

Adrenal cancer is one of the most deadly types of cancer, with few treatment options available. Standard therapy, which causes severe side effects, has been the same for more than 40 years. About 500 people will be diagnosed with adrenal cancer this year in the United States and most will die within five years. The disease is often diagnosed at a late stage and surgery is rarely an option.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Clinical trial tests new treatment for rare cancer." ScienceDaily. ScienceDaily, 15 October 2013. <www.sciencedaily.com/releases/2013/10/131015103645.htm>.
University of Michigan Health System. (2013, October 15). Clinical trial tests new treatment for rare cancer. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2013/10/131015103645.htm
University of Michigan Health System. "Clinical trial tests new treatment for rare cancer." ScienceDaily. www.sciencedaily.com/releases/2013/10/131015103645.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins